NIVF

NewGen records strong balance sheet with total assets of US$32.7 million Net profit attributable to shareholders of the Company of US$9.9 million BANGKOK, May 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today outlined several highlights of its fiscal year 2025 results and the steady progress of its continued strategic transformation. More information on NewGen’s results can be found in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, (the “2025 Annual Report”) which was filed with the U.S. Securities and Exchange Commission (the “SEC”) in April 2026. The full 2025 Annual Report can be viewed on the Company’s IR website at https://investors.newgenivf.com/financials/annual-reports. Key Financial and Operating Highlights Total assets as of December 31, 2025, were US$32.7 million, compared to US$3.6 million as of December 31, 2024. This represents total assets per share of US$135.9 as of December 31, 2025. Net profit attributable to shareholders of the Company for the year ended December 31, 2025, was US$9.9 million, primarily attributable to bargain purchase gain on the acquisition of the Company’s Nodexus and Microsort businesses. In July 2025, the Company successfully completed the acquisition of advanced cytometry intellectual property, which was subsequently independently valued at US$17.9 million by a “big-four” accounting firm, generating a total bargain purchase gain of US$19.2 million. In November 2025, the Company authorized a US$2 million share repurchase program, reflecting management’s confidence in the Company’s intrinsic value. The Company continued to make progress in the development of its diversification initiatives, including digital asset innovation through NewGenDigital and health supplements through NewGenSup. Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, “Our fiscal year 2025 results reflect the successful execution of our ongoing strategic transformation. With total assets of over US$32 million and a significant profit for fiscal year 2025, we have demonstrated that our diversification strategy is delivering tangible results. We remain focused on building long-term shareholder value and believe our current financial position and growth trajectory provide a strong foundation for continued success.” About NewGen NewGenIVF Group is a tech-forward, diversified, multi-jurisdictional high-growth entity capitalizing on emerging opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through three strategic business divisions that leverage cutting-edge technology and innovative solutions to drive sustainable growth and high ROI for shareholders across multiple global markets. These include “NewGenProperty”, which was established to explore and operate lucrative real estate development projects in the UAE’s Ras Al Khaimah Emirate; “NewGenDigital”, which serves as the Company’s digital asset and DeFi solutions arm; and “NewGenSup”, which focuses on health and longevity products and solutions. NewGen’s legacy business involves providing industry-leading IVF and assisted reproductive treatment services across Asia. With operations spanning multiple jurisdictions and a commitment to innovative, technology-enabled solutions, NewGenIVF Group is uniquely positioned to capitalize on the convergence of real estate, healthcare and digital asset opportunities in the evolving global economy. To learn more, visit www.nivf.global. The information contained on, or accessible through, NewGen’s website is not incorporated by reference into this press release, and you should not consider it a part of this press release. Forward-Looking Statements This press release contains forward-looking statements, which reflect the Company’s current expectations and projections about future events and may include, without limitation, statements regarding the Company's strategic transformation and diversification initiatives; the integration and expected contribution of the Nodexus and Microsort businesses and the value of the acquired cytometry intellectual property; the development and growth of the Company's digital asset innovation business through NewGenDigital and its health supplements business through NewGenSup; the Company's anticipated future financial performance, asset base, and profitability; the implementation of the Company's share repurchase program; and the Company's plans and objectives to build long-term shareholder value. Forward-looking statements are often identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “target,” “will,” and similar expressions, or their negatives, although not all forward-looking statements contain these identifying words. These statements are based on management’s current beliefs, assumptions, and expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, risks related to the integration of the Nodexus and Microsort businesses and the Company's ability to realize the anticipated benefits of those acquisitions; the accuracy of estimates and assumptions used in determining the bargain purchase gain and the fair value of the acquired intellectual property; risks associated with the Company's diversification into digital asset innovation and health supplements, including the evolving regulatory environment applicable to those businesses; the timing, amount, and execution of repurchases under the Company's share repurchase program, which may be modified, suspended, or discontinued at any time; the Company's ability to grow its asset base and improve its operating performance; and the Company's ability to execute on its strategic plans, as well as other risk factors described in the Company’s public disclosures from time to time, including the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Investor Relations Contact ICR, LLC Robin Yang Phone: +1 (212) 537-3847 Email: [email protected]

By Michael Kim NASDAQ: NIVF READ THE FULL NIVF RESEARCH REPORT Ahead of 4Q25/full-year 2025 results likely to be announced later this month, we highlight several key strategic/financial announcements during the quarter: 1. Doubling down on UAE real estate project: In June 2025, NewGenIVF (NASDAQ: NIVF) announced plans to invest $45 million to acquire, develop, and resell real estate properties across the United Arab Emirates. Subsequently, the company acquired a plot of land in Ras Al Khaimah (RAK), the largest city and capital of the Emirate of Ras Al Khaimah, and established a joint venture with BNW Real Estate Development LLC, a real estate developer in Dubai, to help facilitate the design, construction, and marketing of the property. The project site is positioned in RAK’s Beach District, neighboring Al Marjan Island (the location of the Wynn Al Marjan Island resort set to open in early 2027), with plans to develop a luxury residential complex with 525,000+ square feet of Gross Floor Area (GFA) expected to be completed in 2028. Fast forward to December of last year, NIVF announced plans to exercise an option to convert the existing Joint Venture structure into a Joint Development structure, thereby transitioning project financing, development costs, pre-sales expenses, and financial escrow requirements to NewGenProperty, while upping the company’s profit participation potential related to the RAK project from ~$67 million to ~$123 million based on feasibility analyses. Under the new structure, the company plans to raise additional capital to fund NIVF’s incremental financial commitments. 2. Share repurchase authorization: As disclosed in November 2025, the Board of Directors authorized a share repurchase program. Terms of the authorization include the capacity to buy back $2 million of the company’s Class A Ordinary Shares over two years. Stepping back, share repurchases further enhance shareholder alignment, while reinforcing management’s conviction in prospective growth prospects, as well as the stock’s discounted valuation. Following the approval of 1:3 and 1:4 reverse stock splits in December 2025 and February 2026, respectively, the number of Class A Ordinary Shares outstanding was reduced to 568,323. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

By Michael Kim NASDAQ:NIVF Pre-market open on 12/2/25, NewGenIVF Group (NASDAQ:NIVF) reported financial results for the nine months ended September 30, 2025. Following our review of YTD results, we highlight the following key takeaways: 1. Financials mostly tracking in line with our full-year estimates: On a GAAP basis, NIVF reported net income of $17.5 million for the nine months ended 9/30/25, or $96.76 per basic share, representing a considerable turnaround from a net loss of $416K, or $205.97 per share, for the prior-year period. Much of the year-over-year improvement can be attributed to non-cash bargain purchase gains totaling $23.4 million related to the recent acquisitions of MicroSort technology and advanced cytometry intellectual property and equipment from Nodexus. For reference, our model calls for net income of $17.5 million for 2025. Focusing on the top line, NIVF generated year-to-date (YTD) total revenues of $3.3 million compared to $4.2 million for the first three quarters of 2024. After factoring in cost of revenues of $2.9 million, gross profit totaled $0.4 million for the first nine months of 2025 translating into a gross margin of 13.1%. YTD operating expenses totaled $6.2 million versus $1.4 million for the prior-year period, with much of the step up related to higher general & administrative costs associated with ongoing strategic initiatives to further expand and diversify the company’s portfolio of businesses (discussed next). Following through, NIVF reported a YTD operating loss of $5.8 million compared to $71K for the first three quarters of 2024. That said, the company generated $23.2 million of non-operating income for the nine months ended 9/30/25 compared to a loss of $347K for the prior-year period. Looking ahead, we will wait until NIVF reports full-year 2025 results to formally update our earnings model. 2. Plenty of growth catalysts: Beyond the core IVF business, management remains proactive in further building out the company’s portfolio of businesses, thereby enhancing growth prospects and sustainability – likely driving an outsized upward revaluation for the stock over time, we believe. a. Transformational acquisition: First and foremost, the company recently announced the execution of a non-binding term sheet related to a proposed merger with SAXA, Inc., an international holding company focused on high-value mining assets. Terms of the proposed transaction include the issuance of 500 million Class A shares of NIVF stock to SAXA shareholders in exchange for: 1) placer mining claims on 640 acres in La Paz County, Arizona administered by the U.S. Bureau of Land Management (BLM); and 2) claims on 440 acres in California wherein ore samples were found to contain recoverable gold, silver, and Rare Earth Elements (REEs). Focusing on the Arizona gold and silver mine, the most recent NI 43-101 technical report estimates life-of-mine production of 1.9 million ounces of gold and 4.4 million ounces of silver translating into total sales of $8.1 billion based on recent Au and Ag prices. After accounting for equipment, mining costs, and taxes, we put cumulative net cash flows at $4.8 billion over 10 years. After layering in an initial mine acquisition cost of $25 million along with $124 million of development/expansion expenses, and assuming a 10% discount rate (at the high end of precious metal mining projects in similar jurisdictions), we calculate a Net Present Value (NPV) of $2.3 billion for the Arizona project. Turning to the Gold Earths & Mineral Strategies (GEMS) processing facility, management is allocating $1.5 billion of capital expenditures spread across the next 24 months for engineering, procurement, and construction costs. Importantly, CapEx needs are mostly secured by commitments across structures and funding groups (a key differentiating factor relative to most other junior miners), with deployment front-loaded to expedite production and related cash flows. According to the NI 43-101 technical report, the facility is projected to reach peak revenue of $2.5 billion per year (seemingly based on conservative commodities prices) in year three of operations. After factoring in operating expenses and taxes and assuming a 10% discount rate, we calculate a Net Present Value of $4.2 billion for the GEMS facility. b. Digital asset treasury/tokenization strategies: Senior executives remain focused on pursuing a Digital Asset Treasury (DAT) strategy, with plans to invest up to $30 million in Solana (SOL). As of 11/28/25, the company had acquired 13,000 SOL translating into $1.8 million at current prices. Moreover, the company recently announced a binding term sheet with an investment firm for a digital assets purchase agreement. Pursuant to the term sheet, NIVF maintains the option to sell shares of common stock to the investment firm in exchange for up to 600,000 SOL tokens (~$84 million at current prices), thereby further supporting the company’s DAT strategy. Furthermore, more recent digital assets business opportunities include engagement letters with SAXA and the World Chinese Museum to act as the agent for the tokenization of gold-backed assets and a private art collection, respectively. Initial tranches involve $100 million of gold-backed assets and artwork valued at $2 million, with opportunities to expand tokenizations to $1 billion and $200 million, in that order. From a revenue perspective, NIVF can earn 5% commissions on gold-backed assets sold and a 15% fee on the value of artwork tokenized. Stepping back, tokenization provides for incremental monetization opportunities, partial ownership stakes, and enhanced liquidity across transparent, secure, and efficient markets. c. Real estate kicker: NIVF recently announced plans to invest $45 million to acquire, develop, and resell real estate properties across the United Arab Emirates (UAE). While management anticipates investing in other Emirates (namely, Abu Dhabi) to hedge market risk, the company recently acquired a plot of land in Ras Al Khaimah (RAK), the largest city and capital of the Emirate of Ras Al Khaimah. More specifically, the project site is positioned in RAK’s Beach District neighboring Al Marjan Island (the location of the Wynn Al Marjan Island resort set to open in early 2027), with plans to develop a luxury residential complex with 525,000+ square feet of Gross Floor Area (GFA) expected to be completed in 2028. From a project development standpoint, the company recently formed a Joint Venture with BNW Developments, a premium real estate developer focused on high-rise residential properties in the UAE, to help facilitate the design, construction, and marketing of the property. Our math suggests project sales exceed $450 million, with net profits of ~$200 million. NIVF is entitled to approximately one-third of the net profits based on an initial ~$24 million investment. From a financing perspective, the company recently engaged an investment bank to raise capital to fund the initial purchase and related development costs, as well as build out NIVF’s real estate portfolio over time. 3. Strengthening the balance sheet: As of 9/30/25, NIVF’s book value totaled $28.7 million, of $66.75 per share based on 430,540 shares outstanding (adjusted for the recent 1-for-5 reverse stock split) compared to a shareholder deficit of $1.5 million as of 12/31/24. Much of the step-up reflected higher intangible assets related to recent acquisitions. Importantly, the Board of Directors recently authorized a $2 million share repurchase program, thereby further enhancing shareholder alignment, while reinforcing management’s conviction in prospective growth prospects and pending transactions. VALUATION Turning to valuation, our DCF-derived price target for standalone NIVF is based on explicit EBIT forecasts through 2028, a cyclical EBIT trajectory thereafter, a perpetual growth rate of 3% (despite sustainably higher growth rates for the foreseeable future), and an exit EV/EBITDA multiple of 3x. Looking ahead, assuming the reverse merger with SAXA closes, our work suggests considerable upside for NIVF shares on a pro forma basis. More specifically, we calculate NPVs of $2.3 billion and $4.2 billion for the AZ mine and GEMS facility, respectively, and ascribe $88 million of value to the CA project based on a potential resource value of $8.8 billion (440 acres at $20 million/acre). We generally use 1% of resource value for a project at this early stage reflecting considerable uncertainty and the work required to further advance the project through to development. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or “the Company”), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today reported its unaudited financial results for the nine months ended September 30, 2025. Financial Highlights for the Nine Months Ended September 30, 2025 Net income attributable to the shareholders of the Company was $17.5 million, a significant improvement from a net loss of $416,400 in the same period of 2024. This was primarily due to a non-cash, bargain purchase gain recognized on the acquisition of Nodexus and Microsort businesses. Basic earnings per share was $96.76 for the nine months ended September 30, 2025 while losses per share for the nine months ended September 30, 2024 was $205.97. Net book value per share improved to $66.75 from negative net book value as of December 31, 2024, representing a significant balance sheet transformation driven by strategic acquisitions of high-value intellectual property assets. Business Highlights for the Nine Months Ended September 30, 2025 The Company has made significant progress in executing its strategic pivot and diversification strategy throughout 2025. Key initiatives and achievements demonstrating this progress include: Transformative Acquisitions: The Company completed two key acquisitions. On February 28, 2025, the Company acquired the MicroSort® sperm-sorting technology, enhancing its capabilities in the fertility services market. The acquisition also resulted in a prior bargain purchase gain of $4.28 million based on an independent valuation report. On July 29, 2025, the Company acquired advanced cytometry intellectual property and equipment from Nodexus. An independent valuation by a “big-four” accounting firm received in October 2025 confirmed a fair value of $17.9 million for the IP, resulting in a total bargain purchase gain of $19.16 million. This acquisition is central to the Company’s pivot towards a high-margin, technology-licensing business model. 2025 Debt Financing: On April 1, 2025, the Company entered into a Securities Purchase Agreement for the issuance of senior convertible notes with an aggregate principal amount of up to $28.8 million. The first tranche of $3.2 million was received on June 3, 2025, providing capital to fund our strategic initiatives. Expansion into Digital Assets: The Company is actively building its digital asset portfolio, including a plan to invest in Solana (SOL). On June 2, 2025, the Company announced a plan to invest up to $30 million in SOL, and has, as of November 28, 2025, acquired 13,000.23 SOL. The Company has also been engaged to tokenize a $2 million private art collection and a $100 million tranche of gold-backed assets, representing new, potentially high-margin revenue streams. Strategic Joint Venture in UAE Real Estate: Through its subsidiary, and as disclosed on October 8, 2025, the Company entered into a joint venture to develop a strategic plot of land in Ras Al Khaimah, UAE, securing a 60% ownership interest and is positioned to benefit from the project’s gross revenue. Proposed Reverse Merger: The Company is exploring a potential reverse merger with SAXA, Inc., which would provide access to a portfolio of mining assets, including a validated gold and silver mine. Share Repurchase Program: In November 2025, the Company’s Board of Directors authorized a share repurchase program of up to $2 million over 24 months, reflecting management’s confidence in the intrinsic value of the Company. Reverse Stock Split: On November 10, 2025, the Company announced a one-for-five reverse stock split of its issued and unissued shares (the “Reverse Stock Split”). The Reverse Stock Split became effective on Monday, December 1, 2025 and the Company’s Class A Ordinary Shares began trading on the Nasdaq Capital Market on a split-adjusted basis at the opening of market on December 1, 2025. Management Commentary Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, “The nine months ended September 30, 2025 represent an important period for NewGen, with net income of $17.5 million compared to a net loss in the prior year. This improvement was driven by our strategic focus on acquiring high-value intellectual property. The acquisition of Nodexus business including but not limited to advanced cytometry IP generated a bargain purchase gain and increased our net asset value per share to $66.75, positioning us as a technology-driven company with a licensing model that we can scale globally.” “Beyond this core transformation, we embraced the execution of a diversified growth strategy across multiple high-potential sectors. Our digital asset initiatives include strategic Solana treasury positioning and exclusive tokenization mandates in art- and gold-backed assets, representing significant new revenue opportunities. Meanwhile, our UAE real estate joint venture provides direct access to promising Middle Eastern development projects with attractive revenue-sharing terms. Combined with our newly reinforced balance sheet, we believe this unique combination of proprietary technology assets, strategic market positioning, and strong execution creates compelling long-term value for our shareholders.” Nine Months Ended September 30, 2025 Financial Results Revenues: Total revenues were $3.3 million for the nine months ended September 30, 2025, compared to $4.2 million from the same period 2024. Cost of Revenues: Cost of revenues was unchanged at $2.9 million, compared to the previous year. Total Other Income: Total other income, net, was $23.20 million for the nine months ended September 30, 2025, a substantial improvement from other losses, net, $346,748 in the prior year period. This was primarily due to a non-cash, bargain purchase gain of $23.44 million recognized on the acquisition of Nodexus and Microsort businesses including but not limited to its intellectual property and trademarks based on two independent valuation reports. General and Administrative Expenses: General and administrative expenses were $5.7 million, compared to $1.1 million for the nine months ended September 30, 2024. The increase was primarily attributable to costs associated with supporting the Company’s expanding strategic initiatives and corporate development activities. Net Income: Net income attributable to the shareholders of the Company was $17.5 million, a significant improvement from a net loss of $416,400 in the same period of 2024. This result was primarily driven by a $23.44 million gain from bargain purchases on acquisitions. About NewGenIvf Group Limited NewGenIvf Group Limited (NASDAQ: NIVF) is a tech-forward, diversified, multi-jurisdictional company transforming industries through innovative solutions. The Company is strategically pivoting from its foundation in fertility services to a technology-driven model centered on the licensing of proprietary reproductive technologies. This core is augmented by strategic growth vectors in digital asset management, including tokenization services and a Solana treasury strategy, and real estate development through a joint venture in the UAE. NewGen is focused on building a high-growth, diversified ecosystem that leverages blockchain technology and strategic acquisitions to drive long-term shareholder value. Safe Harbor Statements This news release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “going forward,” “outlook,” and similar statements. Forward-looking statements in this 6-K include, but are not limited to, statements regarding: (i) the Company’s strategic pivot to a technology-licensing business model and its ability to generate licensing revenue from acquired intellectual property; (ii) plans to invest in digital assets, including Solana, and the Company’s digital asset treasury strategy; (iii) tokenization services and revenue opportunities related to art collections and gold-backed assets; (iv) the anticipated benefits and revenue potential from the UAE real estate joint venture; (v) the potential reverse merger with SAXA, Inc and access to mining assets; (vi) the Company’s diversified growth strategy and ability to execute across multiple business sectors; and (vii) the Company’s financial condition, liquidity, and ability to fund its strategic initiatives. These forward-looking statements are based on management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties, and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: (i) the Company’s ability to successfully commercialize and license acquired intellectual property; (ii) uncertainty regarding the actual fair value of acquired intangible assets and potential future impairment charges; (iii) risks that independent valuations may not reflect actual market value or revenue generating potential; (iv) regulatory requirements and restrictions affecting reproductive technologies in various jurisdictions; (v) extreme volatility in digital asset markets, including Solana; (vi) the Company’s limited operating history in multiple new business segments and unproven business models; (vii) management’s ability to effectively oversee business operations across multiple jurisdictions; (viii) uncertainties regarding the ability to fund, develop, obtain permits and complete the UAE real estate project; and (ix) the Company’s ability to secure additional financing on favorable terms or at all. The risks and uncertainties described above are not exhaustive. Additional risks and uncertainties not presently known to the Company may also adversely affect the Company’s business, financial condition, results of operations, and prospects. These factors may cause the Company’s actual results, performance, or achievements to differ materially from those in the forward-looking statements. Investors are urged to carefully review and consider the various disclosures made by the Company in this release and in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required under applicable law. Readers should not rely upon the information in this news release as current or accurate after its publication date. For more information: Investor Relations Contact ICR, LLC Robin Yang Phone: +1 (212) 537-4406 Email: [email protected] The accompanying notes are an integral part of these consolidated financial statements. The accompanying notes are an integral part of these consolidated financial statements.